Brown Advisory Inc. purchased a new stake in Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 550,418 shares of the company's stock, valued at approximately $13,716,000. Brown Advisory Inc. owned approximately 1.07% of Kestra Medical Technologies as of its most recent SEC filing.
Kestra Medical Technologies Stock Performance
Shares of KMTS traded up $0.52 during mid-day trading on Monday, hitting $15.43. 219,410 shares of the company's stock were exchanged, compared to its average volume of 253,627. Kestra Medical Technologies, Ltd. has a fifty-two week low of $14.02 and a fifty-two week high of $26.15. The company has a 50 day simple moving average of $19.53.
Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) last announced its quarterly earnings data on Monday, April 14th. The company reported ($1.25) EPS for the quarter, missing analysts' consensus estimates of ($0.64) by ($0.61). During the same quarter in the previous year, the business posted ($1.18) EPS.
Analyst Ratings Changes
A number of equities research analysts have recently issued reports on KMTS shares. Stifel Nicolaus started coverage on Kestra Medical Technologies in a research report on Monday, March 31st. They issued a "buy" rating and a $28.00 price target for the company. The Goldman Sachs Group decreased their price objective on Kestra Medical Technologies from $24.00 to $23.00 and set a "neutral" rating on the stock in a report on Wednesday, April 16th. Bank of America started coverage on Kestra Medical Technologies in a research note on Monday, March 31st. They set a "buy" rating and a $30.00 price target on the stock. Wolfe Research initiated coverage on Kestra Medical Technologies in a research note on Monday, March 31st. They set an "outperform" rating and a $29.00 price target on the stock. Finally, Wells Fargo & Company assumed coverage on Kestra Medical Technologies in a research report on Monday, March 31st. They set an "overweight" rating and a $28.00 price objective on the stock. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. According to MarketBeat.com, Kestra Medical Technologies currently has an average rating of "Moderate Buy" and a consensus price target of $27.50.
View Our Latest Stock Analysis on KMTS
Kestra Medical Technologies Profile
(
Free Report)
We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.
See Also
Before you consider Kestra Medical Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kestra Medical Technologies wasn't on the list.
While Kestra Medical Technologies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
